SCHEMBL10130225

SCHEMBL10130225

C[C@@H]1CCN(CC2CCCC2)C1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.73
CHRM5 P08912 2/20 0.52
ADRA2C P18825 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SIGMAR1 Q99720 2/20 0.39
GBA1 P04062 1/20 0.38
OPRM1 P35372 2/20 0.37
OPRL1 P41146 2/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM1 P11229 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT1 Q99873 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
SCN1A P35498 1/20 0.35
SCN4A P35499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10998970 1.00 ACHE (0.73) ACHECHRM5ADRA2CSMN1; SMN2KDM4E
SCHEMBL14197722 0.98 ACHE (0.77) ACHECHRM5ADRA2CSMN1; SMN2KDM4E
SCHEMBL20756545 0.96 ACHE (0.67) ACHECHRM5ADRA2CSMN1; SMN2KDM4E
SCHEMBL10130156 0.91 ACHE (0.59) ACHECHRM5ADRA2CKDM4ESIGMAR1
SCHEMBL478539 0.91 ACHE (0.59) ACHECHRM5ADRA2CKDM4ESIGMAR1
SCHEMBL10130194 0.91 ACHE (0.59) ACHECHRM5ADRA2CKDM4ESIGMAR1
SCHEMBL12950313 0.89 ACHE (0.59) ACHECHRM5ADRA2CKDM4E
SCHEMBL1201944 0.88 ACHE (0.62) ACHECHRM5ADRA2CSMN1; SMN2KDM4E
SCHEMBL10130279 0.86 ACHE (0.95) ACHECHRM5ADRA2CSMN1; SMN2OPRM1
SCHEMBL24315887 0.84 ACHE (1.00) ACHECHRM5ADRA2CSMN1; SMN2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 ACHE 1146/4885CHRM5 1420/4885ADRA2C 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.